Patents by Inventor Michael Gary Nicholls
Michael Gary Nicholls has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10106575Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: GrantFiled: March 16, 2017Date of Patent: October 23, 2018Assignee: Upstream Medical Technologies LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20180051050Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: ApplicationFiled: March 16, 2017Publication date: February 22, 2018Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Patent number: 9630985Abstract: The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: GrantFiled: March 12, 2009Date of Patent: April 25, 2017Assignee: Otago Innovation LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20160258967Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: March 6, 2016Publication date: September 8, 2016Applicant: OTAGO INNOVATION LIMITEDInventors: Christopher Joseph PEMBERTON, Arthur Mark RICHARDS, Michael Gary NICHOLLS, Timothy Grant YANDLE
-
Patent number: 9255930Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: GrantFiled: April 15, 2013Date of Patent: February 9, 2016Assignee: OTAGO INNOVATION LIMITEDInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20130316378Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: April 15, 2013Publication date: November 28, 2013Applicant: OTAGO INNOVATION LIMITEDInventors: Christopher Joseph PEMBERTON, Arthur Mark RICHARDS, Michael Gary NICHOLLS, Timothy Grant YANDLE
-
Patent number: 8507209Abstract: The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: GrantFiled: March 12, 2009Date of Patent: August 13, 2013Assignee: Otago Innovation LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20130183683Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: April 4, 2012Publication date: July 18, 2013Inventors: Christopher Joseph PEMBERTON, Arthur Mark RICHARDS, Michael Gary NICHOLLS, Timothy Grant YANDLE
-
Patent number: 8298772Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: GrantFiled: March 6, 2009Date of Patent: October 30, 2012Assignee: Otago Innovation LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20110104723Abstract: The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: ApplicationFiled: March 12, 2009Publication date: May 5, 2011Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Publication number: 20110033874Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring ANP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. Also provided are antibodies useful in the methods of the invention.Type: ApplicationFiled: February 20, 2009Publication date: February 10, 2011Applicant: OTAGE INNOVATION LIMITEDInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20110008808Abstract: The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.Type: ApplicationFiled: March 12, 2009Publication date: January 13, 2011Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
-
Publication number: 20090239246Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: March 6, 2009Publication date: September 24, 2009Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle